Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
Octreotide is a somatostatin analog with a long half-life in vivo. Octreotide has interesting
anti-inflammatory and anti-fibrotic properties in vitro and in vivo. Somatostatin receptors
are increased and Octreotide uptake is increased in the lung in patients with idiopathic
pulmonary fibrosis. Our hypothesis is that octreotide may slow the degradation of lung
function in patients with IPF. In this proof of concept study, patients with IPF will receive
an intramuscular injection of slow release octreotide (Sandostatin LP, 30 mg)every 4 weeks
for 48 weeks. Lung function (FVC, DLCO), HRCT scores for fibrosis and ground glass, 6 minute
walking test,quality of life and survival will be monitored.